LearnGlossaryMarketStocksSuperinvestorsSign in

PCRX

Pacira BioSciences, Inc.

Healthcare · $988M market cap

Verdict

Share price

$25.21

close of Oct 3, 2026

Fair value

$32.88

Sticker Price

Payback Price

$13.15

buy price

Undervalued

PCRX is Undervalued: at $25.21 it trades 23% below its fair value of $32.88. Its buy price (Payback Price) is $13.15, 48% below today's price. Business quality is solid: 3 of 5 key numbers clear the 10% bar.

How we valued it

Free Cash Flow. Sales grew 3% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-22.8% a year✗
Equity per share growth16.9% a year✓
Sales growth13.9% a year✓
Free cash flow growth26.3% a year✓
Return on invested capital0.0%✗

Follow PCRX

Get notified when it reaches its buy price of $13.15. Free.

Create a free account

About Pacira BioSciences, Inc.

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a…

Drug Manufacturers - Specialty & Generic

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works